VidaMed shareholders file complaint over Medtronic deal
This article was originally published in Clinica
Executive Summary
VidaMed has rejected accusations, believed to be filed by its shareholders, concerned with its recently-announced plans to be bought by Medtronic. The Fremont, California company says the complaints include breach of fiduciary duty by its directors in relation to the proposed merger. Three complaints have been filed against the company, its directors and Medtronic. VidaMed will defend its position.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.